Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.59 |
| ▸ | LSS | P48449 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1020230 | 0.91 | HRH3 (0.58) | KDM4EALDH1A1SMN1; SMN2HRH3CA1 | |
| SCHEMBL9671156 | 0.84 | KDM4E (0.83) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL31090233 | 0.82 | KDM4E (0.62) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL3698312 | 0.81 | THRA (0.52) | HRH3CA1CA2 | |
| SCHEMBL2557697 | 0.81 | FDPS (0.47) | KDM4EALDH1A1SMN1; SMN2CA1CA2 | |
| SCHEMBL623764 | 0.81 | CA1 (0.57) | CA1CA2ENPP2LTA4H | |
| SCHEMBL1477066 | 0.79 | KDM4E (0.69) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| Hydrochloric Acid SCHEMBL10806159 | 0.78 | KDM4E (0.67) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL1006706 | 0.78 | NR5A1 (0.61) | CA1CA2LTA4H | |
| SCHEMBL2561437 | 0.78 | CA2 (0.55) | CA1CA2ENPP2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| US-11547703-B2 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2023-01-10 | — | — | US | disclosed |
| CN-110312717-B | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and uses thereof | 上海瑛派药业有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20210128535-A1 | Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2021-05-06 | — | — | US | disclosed |
| EP-2755642-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | Seattle Genetics, Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013055990-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | SEATTLE GENETICS, INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | AMMENN ET AL, JOCHEN | 2005-12-08 | — | — | US | disclosed |
| US-20050261331-A1 | Substituted pyrrolopyridines | ASTRAZENECA AB (SE) | 2005-11-24 | — | — | US | disclosed |
| US-20050215582-A1 | Substituted pyrrolopyridines | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | disclosed |
| EP-1539757-A1 | SUBSTITUTED PYRROLOPYRIDINES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1539758-A1 | SUBSTITUTED PYRROLOPYRIDINES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1505968-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004016610-A1 | SUBSTITUTED PYRROLOPYRIDINES | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004016609-A1 | SUBSTITUTED PYRROLOPYRIDINES | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
| WO-2003097047-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128535-A1 | Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof | CHEK2, CHEK1, ATM | KDM4E 1694/4885ALDH1A1 1975/4885SMN1; SMN2 2929/4885 |
| US-20050261331-A1 | Substituted pyrrolopyridines | ITK, WEE1, PDPK1 | KDM4E 1691/4885ALDH1A1 1591/4885SMN1; SMN2 2616/4885 |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | MC1R, MC4R, MC5R | KDM4E 2751/4885ALDH1A1 716/4885SMN1; SMN2 4137/4885 |
| US-20050215582-A1 | Substituted pyrrolopyridines | ITK, WEE1, PDPK1 | KDM4E 1691/4885ALDH1A1 1591/4885SMN1; SMN2 2616/4885 |
| US-11547703-B2 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | CHEK2, CHEK1, ATM | KDM4E 1694/4885ALDH1A1 1975/4885SMN1; SMN2 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.